Dataset Information

Deep proteome profiling of human cerebrospinal fluid from patients diagnosed with Multiple System Atrophy, Parkinson’s Disease, Dementia with Lewy Bodies, Progressive Supranuclear Palsy, and from Controls

ABSTRACT: Human cerebrospinal fluid was collected from patients diagnosed with neurodegenerative diseases including multiple system atrophy (n=28), Parkinson’s disease (n=40), dementia with Lewy bodies (n=20), progressive supranuclear palsy (n=39) and from controls (n=17) in order to perform a comparative quantitative proteome profiling of cerebrospinal fluids from the five groups.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cerebrospinal Fluid

DISEASE(S): Lewy Body Dementia,Progressive Supranuclear Palsy,Disease Free,Multiple System Atrophy,Parkinson's Disease

SUBMITTER: Ole Østergaard

LAB HEAD: Jesper Velgaard Olsen

PROVIDER: PXD026802 | Pride | 2022-08-12

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20200123_QE5_Evo3_OOE_DIA-120k-15k-2s-45min_CSF-A-01-E.raw	Raw
	20200123_QE5_Evo3_OOE_DIA-120k-15k-2s-45min_CSF-A-02-E.raw	Raw
	20200123_QE5_Evo3_OOE_DIA-120k-15k-2s-45min_CSF-A-03-E.raw	Raw
	20200123_QE5_Evo3_OOE_DIA-120k-15k-2s-45min_CSF-A-04-E.raw	Raw
	20200123_QE5_Evo3_OOE_DIA-120k-15k-2s-45min_CSF-A-05-E.raw	Raw

Items per page:

1 - 5 of 439

Publications

Brain proteome profiling implicates the complement and coagulation cascade in multiple system atrophy brain pathology.

Rydbirk Rasmus R Østergaard Ole O Folke Jonas J Hempel Casper C DellaValle Brian B Andresen Thomas L TL Løkkegaard Annemette A Hejl Anne-Mette AM Bode Matthias M Blaabjerg Morten M Møller Mette M Danielsen Erik H EH Salvesen Lisette L Starhof Charlotte C CC Bech Sara S Winge Kristian K Rungby Jørgen J Pakkenberg Bente B Brudek Tomasz T Olsen Jesper V JV Aznar Susana S

Cellular and molecular life sciences : CMLS 20220603 6

<h4>Background</h4>Multiple system atrophy (MSA) is a rare, progressive, neurodegenerative disorder presenting glia pathology. Still, disease etiology and pathophysiology are unknown, but neuro-inflammation and vascular disruption may be contributing factors to the disease progression. Here, we performed an ex vivo deep proteome profiling of the prefrontal cortex of MSA patients to reveal disease-relevant molecular neuropathological processes. Observations were validated in plasma and cerebrospi ...[more]

PMID: 35657417

Similar Datasets

Project description:HIGHTLIGHTS-Improved protocol for ISF collection using microdialysis and CSF sampling in mice.-Combined LC‒MS/MS proteomics ISF and CSF analyses for the validation and description of potential new AD biomarkers.-ISF proteomics analysis to track disease progression at the neuronal and glial levels.-Identification of new biomarker candidates for Alzheimer’s disease.ABSTRACTBackground: Mass spectrometry (MS)-based cerebrospinal fluid (CSF) proteomics is an important method for discovering biomarkers of neurodegenerative diseases. CSF serves as a reservoir for interstitial fluid (ISF), and extensive communication between the two fluid compartments helps to remove waste products from the brain.New method: We performed proteomic analyses of both CSF and ISF fluid compartments using intracerebral microdialysis to validate and detect novel biomarkers of Alzheimer's disease (AD) in APPtg and C57Bl/6J control mice.Results: We identified up to 625 proteins in ISF and 4,483 proteins in CSF samples. By comparing the biofluid profiles of APPtg and C57Bl/6J mice, we detected 37 and 108 significantly up- and downregulated candidates, respectively. In ISF, 7 highly regulated proteins, such as Gfap, Aldh1l1, Gstm1, and Txn, have already been implicated in AD progression, whereas in CSF, 9 out of 14 highly regulated proteins, such as Apba2, Syt12, Pgs1 and Vsnl1, have also been validated to be involved in AD pathogenesis. In addition, we also detected new interesting regulated proteins related to the control of synapses and neurotransmission (Kcna2, Cacng3, and Clcn6) whose roles as AD biomarkers should be further investigated.Comparison with existing methods: This newly established combined protocol provides better insight into the mutual communication between ISF and CSF as an analysis of tissue or CSF compartments alone.Conclusions: The use of multiple fluid compartments, ISF and CSF, for the detection of their biological communication enables better detection of new promising AD biomarkers.KEYWORDSAlzheimer’s disease, CSF, ISF, proteomics, biomarkers, microdialysis, mass spectrometry, protein identification, neurodegeneration, brain fluids, expression profilesDATA AVAILABILITYDOI: 10.17605/OSF.IO/VWQ58PUBLICATIONS using this dataset:1)Gorska et al. 2024, Journal of Neuroscience Methodshttps://doi.org/10.1016/j.jneumeth.2024.1102392) to come